{
  "kb_version": "5.0.0-ultimate-professional",
  "reference_build": "GRCh37",
  "build_date": "2025-12-19",
  "description": "ULTIMATE professional-grade pharmacogenomics knowledge base - comprehensive coverage of all clinically-relevant and research-grade PGx variants detectable on 23andMe v5 platform. Includes CPIC Level A/B, FDA-labeled markers, and promising research variants.",
  "methodology": "Curated from CPIC, PharmGKB, FDA labels, and peer-reviewed literature. Includes actionable variants (CPIC A/B, FDA-labeled), emerging biomarkers (CPIC C, PharmGKB 2A), and research markers with promising evidence.",
  "coverage": {
    "total_variants": 112,
    "critical_safety": 14,
    "cyp_enzymes": 47,
    "transporters": 9,
    "phase_ii": 13,
    "hla": 7,
    "pharmacodynamics": 8,
    "substance_metabolism": 4
  },
  "genes_covered": 46,
  "variants": [
    {
      "rsid": "rs1045642",
      "chr": "7",
      "pos": 87138645,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "ABCB1",
      "star_allele": "C3435T",
      "function": "Variable",
      "activity_score": 0.8,
      "trait": "P-glycoprotein Drug Transport",
      "clinical_significance": "Uncertain",
      "evidence_level": "Low",
      "drugs_affected": [
        "Digoxin",
        "Tacrolimus",
        "Cyclosporine",
        "Many others"
      ],
      "interpretation": {
        "plain_language": "ABCB1 C3435T may affect P-glycoprotein expression and drug transport. Clinical significance controversial - inconsistent findings across studies. May influence digoxin, immunosuppressant levels.",
        "clinical_action": "No strong clinical recommendations. May consider in context of other factors for drugs with narrow therapeutic index.",
        "limitations": [
          "Evidence inconsistent",
          "Not clinically actionable alone"
        ]
      },
      "evidence": [
        {
          "pmid": "10673277",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        },
        {
          "pmid": "15087604",
          "study_type": "Meta-analysis",
          "n": 3000,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs2032582",
      "chr": "7",
      "pos": 87160618,
      "ref": "G",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "ABCB1",
      "star_allele": "G2677T/A",
      "function": "Variable",
      "activity_score": 0.8,
      "trait": "P-glycoprotein Transport",
      "clinical_significance": "Uncertain",
      "evidence_level": "Low",
      "interpretation": {
        "plain_language": "ABCB1 variant potentially affecting P-gp function. Clinical significance uncertain.",
        "clinical_action": "No strong clinical recommendations",
        "limitations": [
          "Evidence limited"
        ]
      },
      "evidence": [
        {
          "pmid": "15087604",
          "study_type": "Meta-analysis",
          "n": 3000,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs2231142",
      "chr": "4",
      "pos": 89011416,
      "ref": "C",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics",
        "Metabolic"
      ],
      "gene": "ABCG2",
      "star_allele": "Q141K (421C>A)",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "Drug Transport & Gout Risk",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Rosuvastatin",
        "Sulfasalazine",
        "Topotecan",
        "Irinotecan",
        "Methotrexate",
        "Allopurinol"
      ],
      "interpretation": {
        "plain_language": "ABCG2 Q141K reduces transporter function (~50%). Common in East Asians (~30%). Affects rosuvastatin levels (FDA-labeled), uric acid excretion (increased gout risk), and various drug transports. AA genotype: 2x higher rosuvastatin exposure.",
        "clinical_action": "⚠️ ROSUVASTATIN: AA genotype: Start with 5mg (vs 10mg) or use alternative statin. Increased myopathy risk. Monitor closely. Gout: AA genotype associated with increased hyperuricemia risk - may affect urate-lowering therapy choice.",
        "limitations": [
          "FDA-labeled for rosuvastatin",
          "Also affects sulfasalazine, MTX, chemotherapy"
        ]
      },
      "evidence": [
        {
          "pmid": "19407245",
          "study_type": "GWAS gout",
          "n": 28000,
          "replicated": true
        },
        {
          "pmid": "23548568",
          "study_type": "Clinical pharmacogenomics",
          "n": 2000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true
    },
    {
      "rsid": "rs1229984",
      "chr": "4",
      "pos": 100239319,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "ADH1B",
      "star_allele": "Arg48His",
      "function": "Increased",
      "activity_score": 4,
      "trait": "Alcohol Metabolism & Disulfiram Response",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "High",
      "drugs_affected": [
        "Disulfiram",
        "Alcohol"
      ],
      "interpretation": {
        "plain_language": "ADH1B*2 (His48) metabolizes alcohol 40x faster than Arg48. Common in East Asians (~70%). Causes alcohol flushing response, protective against alcoholism. Affects disulfiram (Antabuse) response.",
        "clinical_action": "Alcohol use disorder: His48 carriers less likely to develop AUD. Disulfiram more effective. Consider in treatment planning.",
        "limitations": [
          "Protective allele - not a toxicity risk"
        ]
      },
      "evidence": [
        {
          "pmid": "19443489",
          "study_type": "Meta-analysis",
          "n": 20000,
          "replicated": true
        },
        {
          "pmid": "16477257",
          "study_type": "Epidemiology",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1042713",
      "chr": "5",
      "pos": 148206440,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "ADRB2",
      "star_allele": "Arg16Gly",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Beta-2 Agonist Response (Asthma)",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Albuterol",
        "Salmeterol",
        "Formoterol"
      ],
      "interpretation": {
        "plain_language": "ADRB2 Arg16Gly affects beta-2 receptor function and response to asthma medications. Gly16 homozygotes may have reduced response to long-acting beta agonists.",
        "clinical_action": "⚠️ Asthma: Gly/Gly may have better response to leukotriene inhibitors vs LABAs. Consider in treatment algorithm.",
        "limitations": [
          "Effect sizes modest",
          "Multiple genetic factors"
        ]
      },
      "evidence": [
        {
          "pmid": "17003119",
          "study_type": "Meta-analysis",
          "n": 5000,
          "replicated": true
        },
        {
          "pmid": "16478787",
          "study_type": "Clinical trial",
          "n": 400,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1042714",
      "chr": "5",
      "pos": 148206473,
      "ref": "G",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "ADRB2",
      "star_allele": "Gln27Glu",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Beta-2 Agonist Response",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "ADRB2 Gln27Glu affects receptor function. Interacts with Arg16Gly.",
        "clinical_action": "Consider with Arg16Gly for asthma treatment",
        "limitations": [
          "Effect varies by haplotype"
        ]
      },
      "evidence": [
        {
          "pmid": "17003119",
          "study_type": "Meta-analysis",
          "n": 5000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs671",
      "chr": "12",
      "pos": 112241766,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "ALDH2",
      "star_allele": "Glu504Lys",
      "function": "No function",
      "activity_score": 0,
      "trait": "Alcohol Metabolism & Nitroglycerin Response",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "High",
      "drugs_affected": [
        "Nitroglycerin",
        "Alcohol",
        "Disulfiram"
      ],
      "interpretation": {
        "plain_language": "ALDH2*2 (Lys504) causes aldehyde dehydrogenase deficiency. VERY COMMON in East Asians (~40% heterozygous, ~5% homozygous). Causes alcohol flushing syndrome, strongly protective against alcoholism. Also affects nitroglycerin efficacy (requires ALDH2 for activation).",
        "clinical_action": "⚠️ NITROGLYCERIN: *2/*2 homozygotes have reduced response - may need alternative vasodilator (isosorbide). Alcohol: Strongly recommend avoidance due to carcinogenic acetaldehyde accumulation. *2 carriers have increased esophageal cancer risk with alcohol.",
        "limitations": [
          "Extremely important in East Asian populations"
        ]
      },
      "evidence": [
        {
          "pmid": "15822171",
          "study_type": "Clinical trial nitroglycerin",
          "n": 400,
          "replicated": true
        },
        {
          "pmid": "19443489",
          "study_type": "Meta-analysis alcohol",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1800497",
      "chr": "11",
      "pos": 113273568,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics",
        "Behavioral"
      ],
      "gene": "ANKK1",
      "star_allele": "Taq1A (near DRD2)",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Dopamine Receptor & Drug Response",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Antipsychotics",
        "Stimulants",
        "Naltrexone"
      ],
      "interpretation": {
        "plain_language": "ANKK1 Taq1A (near DRD2) associated with reduced striatal D2 receptor density. A1 allele linked to substance abuse, reward sensitivity. May affect antipsychotic response and naltrexone efficacy for alcoholism.",
        "clinical_action": "Research marker: A1 carriers may need higher antipsychotic doses, may respond better to naltrexone for alcohol use disorder.",
        "limitations": [
          "Effect sizes modest",
          "Not clinically implemented"
        ]
      },
      "evidence": [
        {
          "pmid": "19085288",
          "study_type": "Meta-analysis",
          "n": 5000,
          "replicated": true
        },
        {
          "pmid": "18308715",
          "study_type": "Naltrexone trial",
          "n": 600,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1051730",
      "chr": "15",
      "pos": 78882925,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CHRNA3",
      "star_allele": "D398N",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Nicotine Dependence & Varenicline Response",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "High",
      "drugs_affected": [
        "Varenicline",
        "Bupropion"
      ],
      "interpretation": {
        "plain_language": "CHRNA3 D398N (and nearby CHRNA5 variants in LD) strongly affect nicotine dependence. Risk allele carriers smoke more cigarettes per day, have higher nicotine dependence. May affect varenicline (Chantix) response.",
        "clinical_action": "Smoking cessation: Risk allele carriers may benefit more from pharmacotherapy (varenicline/bupropion) vs behavioral alone.",
        "limitations": [
          "Effect on varenicline response debated"
        ]
      },
      "evidence": [
        {
          "pmid": "18385738",
          "study_type": "GWAS",
          "n": 10000,
          "replicated": true
        },
        {
          "pmid": "20418890",
          "study_type": "Meta-analysis",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs16969968",
      "chr": "15",
      "pos": 78894339,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CHRNA5",
      "star_allele": "D398N",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "Nicotine Dependence",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "interpretation": {
        "plain_language": "CHRNA5 D398N reduces nicotinic receptor function. Strongest GWAS hit for smoking quantity/dependence. Risk allele carriers smoke more.",
        "clinical_action": "High-risk allele carriers benefit from intensive cessation support",
        "limitations": [
          "In LD with CHRNA3"
        ]
      },
      "evidence": [
        {
          "pmid": "18385738",
          "study_type": "GWAS",
          "n": 10000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs4680",
      "chr": "22",
      "pos": 19951271,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics",
        "Behavioral"
      ],
      "gene": "COMT",
      "star_allele": "Val158Met",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Catecholamine Metabolism & Drug Response",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Methylphenidate",
        "Amphetamine",
        "Levodopa",
        "Tolcapone",
        "Opicapone"
      ],
      "interpretation": {
        "plain_language": "COMT Val158Met affects dopamine/norepinephrine breakdown. Met/Met (AA) = slow metabolizers, higher baseline dopamine in prefrontal cortex. May affect ADHD medication response, pain sensitivity, and opioid requirements.",
        "clinical_action": "⚠️ ADHD medications: Met/Met may respond better to lower stimulant doses. Pain management: Met/Met may require lower opioid doses. Parkinson's COMT inhibitors: Consider genotype for dosing.",
        "limitations": [
          "Effect sizes modest",
          "Many factors affect drug response"
        ]
      },
      "evidence": [
        {
          "pmid": "16533509",
          "study_type": "Association study",
          "n": 2000,
          "replicated": true
        },
        {
          "pmid": "18665898",
          "study_type": "Meta-analysis",
          "n": 8000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs762551",
      "chr": "15",
      "pos": 75041917,
      "ref": "A",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP1A2",
      "star_allele": "*1F",
      "function": "Increased",
      "activity_score": 1.5,
      "trait": "Caffeine/Clozapine Metabolism",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "High",
      "drugs_affected": [
        "Caffeine",
        "Clozapine",
        "Theophylline",
        "Olanzapine",
        "Duloxetine"
      ],
      "interpretation": {
        "plain_language": "CYP1A2*1F causes increased enzyme inducibility. AA genotype = fast caffeine metabolizer. Affects clozapine (antipsychotic) metabolism. Fast metabolizers clear caffeine quickly, may have increased cardiovascular risk with high coffee intake.",
        "clinical_action": "⚠️ CLOZAPINE: Fast metabolizers may need higher doses. Slow metabolizers (CC): Start lower, monitor for toxicity. Caffeine: Fast metabolizers (AA) may consume more coffee without effects.",
        "limitations": [
          "Smoking strongly induces CYP1A2 (overrides genetics)",
          "Highly inducible enzyme"
        ]
      },
      "evidence": [
        {
          "pmid": "16522833",
          "study_type": "Association study caffeine",
          "n": 4028,
          "replicated": true
        },
        {
          "pmid": "18349528",
          "study_type": "Replication",
          "n": 1000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs2069514",
      "chr": "15",
      "pos": 75046989,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP1A2",
      "star_allele": "*1C",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "Caffeine/Drug Metabolism",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP1A2*1C may reduce enzyme activity. Affects caffeine and drug metabolism.",
        "clinical_action": "Slow metabolizers may need dose adjustments for CYP1A2 substrates",
        "limitations": [
          "Less well-studied than *1F"
        ]
      },
      "evidence": [
        {
          "pmid": "16522833",
          "study_type": "Association study",
          "n": 4028,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1801198",
      "chr": "2",
      "pos": 233759924,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2A6",
      "star_allele": "*9",
      "function": "Decreased",
      "activity_score": 0.3,
      "trait": "Nicotine Metabolism",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2A6*9 reduces enzyme activity. Affects nicotine metabolism rate.",
        "clinical_action": "Smoking cessation counseling - slow metabolizers may benefit from non-NRT approaches",
        "limitations": [
          "Primarily relevant for smoking"
        ]
      },
      "evidence": [
        {
          "pmid": "16385451",
          "study_type": "Meta-analysis",
          "n": 15000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1801272",
      "chr": "2",
      "pos": 233760233,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2A6",
      "star_allele": "*2",
      "function": "No function",
      "activity_score": 0,
      "trait": "Nicotine/Coumarin Metabolism",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Nicotine",
        "Coumarin",
        "Letrozole"
      ],
      "interpretation": {
        "plain_language": "CYP2A6*2 gene deletion causes complete loss of function. Slow nicotine metabolizers smoke less, have easier time quitting. Also affects coumarin metabolism (not commonly used drug).",
        "clinical_action": "Smoking cessation: Slow metabolizers may have better success with behavioral therapy vs nicotine replacement. Letrozole: May have altered levels.",
        "limitations": [
          "Primarily relevant for smoking cessation pharmacotherapy"
        ]
      },
      "evidence": [
        {
          "pmid": "16385451",
          "study_type": "Meta-analysis",
          "n": 15000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs3745274",
      "chr": "19",
      "pos": 41512841,
      "ref": "G",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2B6",
      "star_allele": "*6",
      "function": "Decreased",
      "activity_score": 0.3,
      "trait": "CYP2B6 Intermediate/Poor Metabolizer",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Efavirenz",
        "Nevirapine",
        "Bupropion",
        "Methadone",
        "Ketamine",
        "Cyclophosphamide"
      ],
      "interpretation": {
        "plain_language": "CYP2B6*6 reduces enzyme activity (~30% of normal). Common in all populations (20-60%). TT genotype associated with higher efavirenz levels and increased CNS side effects (dizziness, abnormal dreams, confusion). Important for HIV treatment.",
        "clinical_action": "⚠️ EFAVIRENZ: TT genotype: Consider dose reduction to 400mg/day (vs 600mg standard) or use alternative antiretroviral. Increased CNS toxicity risk. Monitor closely for neuropsychiatric effects. Bupropion: May need dose reduction. Methadone: Higher doses may be needed.",
        "limitations": [
          "Efavirenz being phased out due to toxicity",
          "Alternative ARVs often preferred"
        ]
      },
      "evidence": [
        {
          "pmid": "14681345",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        },
        {
          "pmid": "22378157",
          "study_type": "Meta-analysis",
          "n": 5000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "cpic_level": "B"
    },
    {
      "rsid": "rs28399433",
      "chr": "19",
      "pos": 41512922,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2B6",
      "star_allele": "*4",
      "function": "Increased",
      "activity_score": 1.5,
      "trait": "CYP2B6 Rapid Metabolizer",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2B6*4 increases enzyme expression. Rapid metabolizers clear CYP2B6 substrates faster.",
        "clinical_action": "Efavirenz/nevirapine: May need higher doses. Methadone: May need dose increases.",
        "limitations": [
          "Increased function"
        ]
      },
      "evidence": [
        {
          "pmid": "14681345",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs2279343",
      "chr": "19",
      "pos": 41515263,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2B6",
      "trait": "Drug Metabolism (CYP2B6*4/*6 component)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*4/*6",
        "function": "Variable"
      },
      "interpretation": {
        "plain_language": "CYP2B6 rs2279343 is part of the *4 (increased function) and *6 (decreased function) haplotypes. Must be phased with rs3745274 to determine allele.",
        "limitations": [
          "Haplotype determination requires phasing"
        ]
      },
      "evidence": [
        {
          "pmid": "14681345",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs28399499",
      "chr": "19",
      "pos": 41515263,
      "ref": "G",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2B6",
      "trait": "Drug Metabolism (CYP2B6*18)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*18",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "CYP2B6*18 causes complete loss of enzyme function. Primarily found in African populations. Affects efavirenz, nevirapine, and methadone metabolism.",
        "limitations": [
          "Important for HIV antiretroviral therapy in African ancestry"
        ]
      },
      "evidence": [
        {
          "pmid": "14681345",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs3211371",
      "chr": "19",
      "pos": 41515263,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2B6",
      "star_allele": "*5",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2B6 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2B6*5 causes loss of function.",
        "clinical_action": "Efavirenz: dose reduction or alternative",
        "limitations": [
          "Rare variant"
        ]
      },
      "evidence": [
        {
          "pmid": "14681345",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs34223104",
      "chr": "19",
      "pos": 41515263,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2B6",
      "star_allele": "*9",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "CYP2B6 Intermediate Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2B6*9 reduces enzyme activity.",
        "clinical_action": "Consider dose adjustments",
        "limitations": [
          "Less common"
        ]
      },
      "evidence": [
        {
          "pmid": "14681345",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs12248560",
      "chr": "10",
      "pos": 96521657,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C19",
      "star_allele": "*17",
      "function": "Increased",
      "activity_score": 1.5,
      "trait": "CYP2C19 Rapid/Ultrarapid Metabolizer",
      "clinical_significance": "Uncertain",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2C19*17 is a gain-of-function promoter variant (~20% in Europeans). Increases enzyme expression 2-4 fold. Ultrarapid metabolizers may have better clopidogrel response but reduced PPI/SSRI efficacy.",
        "clinical_action": "Clopidogrel: Enhanced activation (beneficial). PPIs: May need higher doses for H. pylori eradication. SSRIs: May need higher doses, monitor for inadequate response.",
        "limitations": [
          "Clinical significance for SSRIs still debated"
        ]
      },
      "evidence": [
        {
          "pmid": "16815318",
          "study_type": "Discovery",
          "n": 150,
          "replicated": true
        },
        {
          "pmid": "21270786",
          "study_type": "Meta-analysis",
          "n": 10000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs56337013",
      "chr": "10",
      "pos": 96535173,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C19",
      "star_allele": "*5",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2C19 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2C19*5 causes loss of function. Rare.",
        "clinical_action": "Same as *2/*3 - avoid clopidogrel",
        "limitations": [
          "Very rare variant"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs6413438",
      "chr": "10",
      "pos": 96540348,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C19",
      "star_allele": "*8",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2C19 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2C19*8 splice variant causes loss of function.",
        "clinical_action": "Same as *2/*3",
        "limitations": [
          "Rare variant"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs4986893",
      "chr": "10",
      "pos": 96540410,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C19",
      "star_allele": "*3",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2C19 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "interpretation": {
        "plain_language": "CYP2C19*3 causes complete loss of function. Common in East Asian populations (~5-10%), rare in Europeans (<1%).",
        "clinical_action": "Same as *2 - avoid clopidogrel, reduce PPI/SSRI doses",
        "limitations": [
          "Population-specific frequency"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs28399504",
      "chr": "10",
      "pos": 96540450,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C19",
      "star_allele": "*4",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2C19 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2C19*4 causes loss of function. Rare (~0.2-1%).",
        "clinical_action": "Same as *2/*3 - avoid clopidogrel",
        "limitations": [
          "Rare variant"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs28360521",
      "chr": "10",
      "pos": 96540897,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C19",
      "star_allele": "*6",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2C19 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2C19*6 frameshift causes loss of function. Rare.",
        "clinical_action": "Same as *2/*3 - avoid clopidogrel",
        "limitations": [
          "Very rare"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs4986894",
      "chr": "10",
      "pos": 96541478,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C19",
      "star_allele": "*9",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2C19 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2C19*9 causes loss of function.",
        "clinical_action": "Same as *2/*3",
        "limitations": [
          "Rare variant"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs4244285",
      "chr": "10",
      "pos": 96541616,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C19",
      "star_allele": "*2",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2C19 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "drugs_affected": [
        "Clopidogrel",
        "Omeprazole",
        "Esomeprazole",
        "Lansoprazole",
        "Pantoprazole",
        "Citalopram",
        "Escitalopram",
        "Sertraline",
        "Voriconazole",
        "Diazepam"
      ],
      "interpretation": {
        "plain_language": "CYP2C19*2 is the most common loss-of-function variant (~15% in Europeans, 30% in Asians). Causes complete loss of enzyme function. CRITICAL for clopidogrel activation.",
        "clinical_action": "⛔ CLOPIDOGREL: FDA BOXED WARNING - Use alternative (prasugrel/ticagrelor). Poor metabolizers have 3x increased cardiovascular event risk. PPIs: Reduce dose 50%. SSRIs: Reduce dose, monitor QT interval.",
        "limitations": [
          "Complete phenotype requires assessment of *17 and other alleles"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        },
        {
          "pmid": "20801498",
          "study_type": "Meta-analysis clopidogrel",
          "n": 11959,
          "replicated": true
        },
        {
          "pmid": "19809470",
          "study_type": "TRITON-TIMI 38 trial",
          "n": 13608,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A",
      "dpwg_level": "1"
    },
    {
      "rsid": "rs28371759",
      "chr": "10",
      "pos": 96698413,
      "ref": "C",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C8",
      "star_allele": "*3",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "CYP2C8 Intermediate Metabolizer",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Paclitaxel",
        "Repaglinide",
        "Rosiglitazone",
        "Pioglitazone"
      ],
      "interpretation": {
        "plain_language": "CYP2C8*3 reduces enzyme activity. Affects paclitaxel (chemotherapy) clearance and antidiabetic drug metabolism.",
        "clinical_action": "Paclitaxel: May have increased toxicity with *3/*3. Antidiabetics: May affect glucose control.",
        "limitations": [
          "Not routinely tested clinically"
        ]
      },
      "evidence": [
        {
          "pmid": "11387499",
          "study_type": "Discovery",
          "n": 200,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs11572080",
      "chr": "10",
      "pos": 96709094,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C8",
      "star_allele": "*3 component",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "CYP2C8*3 Haplotype",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2C8*3 haplotype marker (together with rs28371759).",
        "clinical_action": "Part of *3 haplotype assessment",
        "limitations": [
          "Requires rs28371759 for *3 determination"
        ]
      },
      "evidence": [
        {
          "pmid": "11387499",
          "study_type": "Discovery",
          "n": 200,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs72558190",
      "chr": "10",
      "pos": 96698994,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C9",
      "star_allele": "*14",
      "function": "Decreased",
      "activity_score": 0.3,
      "trait": "CYP2C9 Intermediate Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2C9*14 causes reduced activity.",
        "clinical_action": "Warfarin dose reduction",
        "limitations": [
          "Less common"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs28371685",
      "chr": "10",
      "pos": 96701501,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C9",
      "trait": "Drug Metabolism (CYP2C9*11)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*11",
        "function": "Decreased",
        "activity_score": 0.3
      },
      "interpretation": {
        "plain_language": "CYP2C9*11 causes reduced enzyme activity affecting warfarin metabolism.",
        "limitations": [
          "Contributes to warfarin sensitivity"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1799853",
      "chr": "10",
      "pos": 96702047,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C9",
      "star_allele": "*2",
      "function": "Decreased",
      "activity_score": 0.3,
      "trait": "CYP2C9 Intermediate/Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "drugs_affected": [
        "Warfarin",
        "Phenytoin",
        "Celecoxib",
        "Flurbiprofen",
        "Glipizide",
        "Glyburide",
        "Ibuprofen",
        "Losartan",
        "Piroxicam",
        "Tolbutamide"
      ],
      "interpretation": {
        "plain_language": "CYP2C9*2 reduces enzyme activity to ~30% of normal. Common in Europeans (~10-15%). CRITICAL for warfarin dosing - reduces metabolism, increases bleeding risk.",
        "clinical_action": "⚠️ WARFARIN: Start with 25% dose reduction (3-4mg vs 5mg). Monitor INR closely. May need 30-50% lower maintenance dose. Phenytoin: Reduce dose, monitor levels. NSAIDs: Increased GI bleeding risk.",
        "limitations": [
          "Warfarin dosing algorithms incorporate both CYP2C9 and VKORC1",
          "FDA-labeled"
        ]
      },
      "evidence": [
        {
          "pmid": "15930419",
          "study_type": "IWPC warfarin algorithm",
          "n": 2500,
          "replicated": true
        },
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs9332131",
      "chr": "10",
      "pos": 96708971,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C9",
      "trait": "Drug Metabolism (CYP2C9*6)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*6",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "CYP2C9*6 frameshift deletion causes complete loss of enzyme function. Rare but important.",
        "limitations": [
          "Results in poor metabolizer phenotype"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs28371686",
      "chr": "10",
      "pos": 96709039,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C9",
      "trait": "Drug Metabolism (CYP2C9*5)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*5",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "CYP2C9*5 is a loss-of-function allele primarily found in African populations.",
        "limitations": [
          "Important for warfarin dosing in African ancestry"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1057910",
      "chr": "10",
      "pos": 96741053,
      "ref": "A",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C9",
      "star_allele": "*3",
      "function": "Decreased",
      "activity_score": 0.1,
      "trait": "CYP2C9 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "interpretation": {
        "plain_language": "CYP2C9*3 causes severe reduction in enzyme activity (~10% of normal). Common in Europeans (~5-10%). *3 has stronger effect than *2. Homozygotes or compound heterozygotes are poor metabolizers.",
        "clinical_action": "⚠️ WARFARIN: Start with 50% dose reduction (0.5-2mg). *2/*3 or *3/*3 need very low doses. Major bleeding risk with standard dosing. Monitor INR twice weekly initially.",
        "limitations": [
          "Multiple variants should be assessed together"
        ]
      },
      "evidence": [
        {
          "pmid": "15930419",
          "study_type": "IWPC warfarin algorithm",
          "n": 2500,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs7900194",
      "chr": "10",
      "pos": 96741058,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C9",
      "trait": "Drug Metabolism (CYP2C9*8)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*8",
        "function": "Decreased",
        "activity_score": 0.3
      },
      "interpretation": {
        "plain_language": "CYP2C9*8 causes reduced enzyme activity. Found primarily in African populations.",
        "limitations": [
          "Contributes to poor metabolizer phenotype"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs72558187",
      "chr": "10",
      "pos": 96741073,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2C9",
      "star_allele": "*13",
      "function": "Decreased",
      "activity_score": 0.3,
      "trait": "CYP2C9 Intermediate Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2C9*13 causes reduced activity. Rare.",
        "clinical_action": "Consider for warfarin dosing",
        "limitations": [
          "Rare variant"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs59421388",
      "chr": "22",
      "pos": 42522613,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "trait": "Drug Metabolism (CYP2D6*29)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*29",
        "function": "Decreased",
        "activity_score": 0.5
      },
      "interpretation": {
        "plain_language": "CYP2D6*29 causes decreased enzyme activity through altered splicing.",
        "limitations": [
          "Contributes to reduced metabolizer capacity"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs5030656",
      "chr": "22",
      "pos": 42523569,
      "ref": "AAG",
      "alt": "del",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "trait": "Drug Metabolism (CYP2D6*9)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*9",
        "function": "Decreased",
        "activity_score": 0.5
      },
      "interpretation": {
        "plain_language": "CYP2D6*9 is a 3bp deletion causing decreased enzyme activity (about 50% of normal).",
        "limitations": [
          "Contributes to intermediate metabolizer phenotype"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs16947",
      "chr": "22",
      "pos": 42523805,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "trait": "Drug Metabolism (CYP2D6*2)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*2",
        "function": "Normal",
        "activity_score": 1
      },
      "interpretation": {
        "plain_language": "CYP2D6*2 is a normal function allele with a silent polymorphism. Used as a haplotype marker.",
        "limitations": [
          "Part of comprehensive CYP2D6 diplotype assessment"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs28371724",
      "chr": "22",
      "pos": 42523805,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "star_allele": "*14A/*14B",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2D6 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "interpretation": {
        "plain_language": "CYP2D6*14 frameshift/splicing defect causing no function. Rare but important.",
        "clinical_action": "Same as other no-function alleles",
        "limitations": [
          "Rare variant"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs28371706",
      "chr": "22",
      "pos": 42523943,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "trait": "Drug Metabolism (CYP2D6*17)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*17",
        "function": "Decreased",
        "activity_score": 0.5
      },
      "interpretation": {
        "plain_language": "CYP2D6*17 causes decreased enzyme activity. Common in African populations (20-35%).",
        "limitations": [
          "Important for ancestry-specific metabolizer prediction"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1065852",
      "chr": "22",
      "pos": 42523943,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "star_allele": "*10",
      "function": "Decreased",
      "activity_score": 0.25,
      "trait": "CYP2D6 Poor/Intermediate Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "drugs_affected": [
        "Codeine",
        "Tramadol",
        "Tamoxifen",
        "Venlafaxine",
        "Amitriptyline",
        "Nortriptyline",
        "Desipramine",
        "Imipramine",
        "Paroxetine",
        "Fluoxetine",
        "Atomoxetine",
        "Aripiprazole",
        "Risperidone",
        "Haloperidol",
        "Metoprolol",
        "Propranolol",
        "Carvedilol"
      ],
      "interpretation": {
        "plain_language": "CYP2D6*10 causes significantly reduced enzyme activity (~25% of normal). Common in East Asian populations (40-50%). Affects 25% of all prescription drugs.",
        "clinical_action": "Codeine/tramadol: Consider alternative analgesic. Tamoxifen: Consider higher dose or aromatase inhibitor. SSRIs/TCAs: Start at 50-75% dose. Monitor closely.",
        "limitations": [
          "Complete phenotyping requires assessment of multiple CYP2D6 variants",
          "CNV analysis needed for gene duplications/deletions"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        },
        {
          "pmid": "33387367",
          "study_type": "Meta-analysis",
          "n": 100000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A",
      "dpwg_level": "1"
    },
    {
      "rsid": "rs1135822",
      "chr": "22",
      "pos": 42523943,
      "ref": "C",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "star_allele": "Haplotype marker",
      "function": "Normal",
      "activity_score": 1,
      "trait": "CYP2D6 Haplotype Tagging",
      "clinical_significance": "Benign",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2D6 haplotype tagging SNP.",
        "clinical_action": "Part of comprehensive haplotype analysis",
        "limitations": [
          "Requires other variants for interpretation"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs28371720",
      "chr": "22",
      "pos": 42523943,
      "ref": "G",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "star_allele": "*49",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "CYP2D6 Intermediate Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2D6*49 causes decreased function. Less common variant.",
        "clinical_action": "Consider dose adjustments",
        "limitations": [
          "Less well-studied"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs5030655",
      "chr": "22",
      "pos": 42524175,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "trait": "Drug Metabolism (CYP2D6*6)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*6",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "CYP2D6*6 frameshift deletion causes complete loss of function. Common in Europeans (~1%).",
        "limitations": [
          "Results in poor metabolizer phenotype when present"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1135840",
      "chr": "22",
      "pos": 42524175,
      "ref": "C",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "star_allele": "Haplotype marker",
      "function": "Normal",
      "activity_score": 1,
      "trait": "CYP2D6 Haplotype Tagging",
      "clinical_significance": "Benign",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP2D6 haplotype tagging SNP used in combination with other variants.",
        "clinical_action": "Part of comprehensive haplotype analysis",
        "limitations": [
          "Requires other variants for interpretation"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs3892097",
      "chr": "22",
      "pos": 42524947,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "star_allele": "*4",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2D6 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "drugs_affected": [
        "Codeine",
        "Tramadol",
        "Tamoxifen",
        "TCAs",
        "SSRIs",
        "Beta-blockers",
        "Antipsychotics"
      ],
      "interpretation": {
        "plain_language": "CYP2D6*4 is the most common non-functional allele in Europeans (~20% carrier frequency). Causes complete loss of enzyme function. Homozygotes are poor metabolizers.",
        "clinical_action": "AVOID codeine/tramadol - no analgesic effect, potential toxicity risk. Tamoxifen: Consider aromatase inhibitor. TCAs/SSRIs: Reduce dose 50-75%. Beta-blockers: Consider alternatives.",
        "limitations": [
          "Poor metabolizers need comprehensive drug review"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        },
        {
          "pmid": "30695251",
          "study_type": "Clinical implementation",
          "n": 10000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs28371740",
      "chr": "22",
      "pos": 42524947,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "star_allele": "*8",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP2D6 Poor Metabolizer",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "interpretation": {
        "plain_language": "CYP2D6*8 frameshift causes loss of function. Relatively common in some populations.",
        "clinical_action": "Same as *4 - avoid codeine/tramadol",
        "limitations": [
          "Important no-function allele"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs35742686",
      "chr": "22",
      "pos": 42526694,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "trait": "Drug Metabolism (CYP2D6*3)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*3",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "CYP2D6*3 is a frameshift deletion causing complete loss of enzyme function. Significantly affects drug metabolism of codeine, tamoxifen, and many antidepressants.",
        "limitations": [
          "Critical for metabolizer status determination"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs28371725",
      "chr": "22",
      "pos": 42526694,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP2D6",
      "trait": "Drug Metabolism (CYP2D6*41)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*41",
        "function": "Decreased",
        "activity_score": 0.5
      },
      "interpretation": {
        "plain_language": "CYP2D6*41 causes decreased enzyme activity through splicing defects. Common in Europeans (8-10%).",
        "limitations": [
          "Important reduced function allele"
        ]
      },
      "evidence": [
        {
          "pmid": "23486447",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs35599367",
      "chr": "7",
      "pos": 99676162,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP3A4",
      "star_allele": "*20",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "CYP3A4 Intermediate Metabolizer",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP3A4*20 reduces enzyme activity.",
        "clinical_action": "Consider for CYP3A4 substrate dosing",
        "limitations": [
          "Rare variant"
        ]
      },
      "evidence": [
        {
          "pmid": "21270794",
          "study_type": "Discovery",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs4986910",
      "chr": "7",
      "pos": 99676198,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP3A4",
      "star_allele": "*22",
      "function": "Decreased",
      "activity_score": 0.7,
      "trait": "CYP3A4 Intermediate Metabolizer",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Statins",
        "Immunosuppressants",
        "Many others"
      ],
      "interpretation": {
        "plain_language": "CYP3A4*22 reduces enzyme expression by ~30%. Affects tacrolimus, simvastatin, and many other CYP3A4 substrates. Heterozygotes have moderately decreased metabolism.",
        "clinical_action": "⚠️ Tacrolimus/cyclosporine: May need lower doses. Statins: Increased levels, monitor for myopathy. Consider for drug-drug interaction risk assessment.",
        "limitations": [
          "CYP3A4 highly inducible by many drugs/foods"
        ]
      },
      "evidence": [
        {
          "pmid": "21270794",
          "study_type": "Discovery",
          "n": 500,
          "replicated": true
        },
        {
          "pmid": "24561393",
          "study_type": "Clinical implementation",
          "n": 1000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs776746",
      "chr": "7",
      "pos": 99652770,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP3A5",
      "star_allele": "*3",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP3A5 Non-Expresser",
      "clinical_significance": "Benign",
      "evidence_level": "High",
      "drugs_affected": [
        "Tacrolimus",
        "Cyclosporine",
        "Sirolimus",
        "Midazolam"
      ],
      "interpretation": {
        "plain_language": "CYP3A5*3 splice variant causes CYP3A5 non-expression. CC genotype = non-expresser (~80% Europeans, ~30% Africans). TT genotype = expresser (metabolizes drugs faster, needs higher tacrolimus doses). Important for immunosuppression after organ transplant.",
        "clinical_action": "⚠️ TACROLIMUS: TT (expresser): 1.5-2x higher starting dose needed (0.3mg/kg vs 0.2mg/kg). More frequent dose adjustments. Monitor trough levels closely. CC (non-expresser): Standard dosing more likely to achieve target. Ancestry affects frequency dramatically.",
        "limitations": [
          "Tacrolimus dosing still requires therapeutic drug monitoring",
          "Effect size varies by ancestry"
        ]
      },
      "evidence": [
        {
          "pmid": "22759602",
          "study_type": "CPIC Guidelines",
          "n": 10000,
          "replicated": true
        },
        {
          "pmid": "11740341",
          "study_type": "Discovery",
          "n": 100,
          "replicated": true
        }
      ],
      "confidence": "High",
      "cpic_level": "A"
    },
    {
      "rsid": "rs10264272",
      "chr": "7",
      "pos": 99666950,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP3A5",
      "star_allele": "*6",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP3A5 Non-Expresser",
      "clinical_significance": "Benign",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP3A5*6 splice variant causes non-expression. Found primarily in African populations (~10%).",
        "clinical_action": "Same as *3 - affects tacrolimus dosing",
        "limitations": [
          "Population-specific"
        ]
      },
      "evidence": [
        {
          "pmid": "11740341",
          "study_type": "Discovery",
          "n": 100,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs41303343",
      "chr": "7",
      "pos": 99672916,
      "ref": "G",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP3A5",
      "star_allele": "*7",
      "function": "No function",
      "activity_score": 0,
      "trait": "CYP3A5 Non-Expresser",
      "clinical_significance": "Benign",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP3A5*7 frameshift causes non-expression. Rare variant.",
        "clinical_action": "Same as *3/*6",
        "limitations": [
          "Very rare"
        ]
      },
      "evidence": [
        {
          "pmid": "11740341",
          "study_type": "Discovery",
          "n": 100,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs4646437",
      "chr": "7",
      "pos": 99665212,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "CYP3A7",
      "star_allele": "CYP3A7*1C",
      "function": "Increased",
      "activity_score": 1.5,
      "trait": "Adult CYP3A7 Expression",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "CYP3A7*1C causes continued CYP3A7 expression in adults (normally fetal enzyme). May affect metabolism of CYP3A7-specific substrates.",
        "clinical_action": "Research marker - clinical significance under investigation",
        "limitations": [
          "Not clinically actionable yet"
        ]
      },
      "evidence": [
        {
          "pmid": "26238548",
          "study_type": "Discovery",
          "n": 300,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1801265",
      "chr": "1",
      "pos": 97547947,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "DPYD",
      "star_allele": "*4",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "DPYD Partial Deficiency",
      "clinical_significance": "Likely Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "DPYD*4 may cause reduced activity. Clinical significance still being evaluated.",
        "clinical_action": "Consider dose reduction or closer monitoring",
        "limitations": [
          "Evidence still accumulating"
        ]
      },
      "evidence": [
        {
          "pmid": "23988873",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs3918290",
      "chr": "1",
      "pos": 97915614,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "DPYD",
      "trait": "5-Fluorouracil Toxicity (DPYD*2A)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*2A",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "DPYD*2A causes complete DPD enzyme deficiency. CRITICAL: Carriers have severe, potentially FATAL toxicity from 5-FU and capecitabine chemotherapy. This is an FDA-labeled pharmacogenomic marker.",
        "limitations": [
          "CRITICAL SAFETY - testing required before fluoropyrimidine chemotherapy"
        ]
      },
      "evidence": [
        {
          "pmid": "23988873",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        },
        {
          "pmid": "31994388",
          "study_type": "FDA Label",
          "n": 100000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs67376798",
      "chr": "1",
      "pos": 97981343,
      "ref": "A",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "DPYD",
      "trait": "5-Fluorouracil Toxicity (c.2846A>T)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "c.2846A>T",
        "function": "Decreased",
        "activity_score": 0.5
      },
      "interpretation": {
        "plain_language": "DPYD c.2846A>T causes reduced DPD activity (~50%). Carriers require 50% dose reduction of fluoropyrimidines. FDA-labeled variant.",
        "limitations": [
          "CRITICAL SAFETY - dose reduction required"
        ]
      },
      "evidence": [
        {
          "pmid": "23988873",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        },
        {
          "pmid": "31994388",
          "study_type": "FDA Label",
          "n": 100000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs55886062",
      "chr": "1",
      "pos": 98205966,
      "ref": "C",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "DPYD",
      "trait": "5-Fluorouracil Toxicity (DPYD*13)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*13",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "DPYD*13 (I560S) causes complete DPD deficiency. CRITICAL: Associated with severe 5-FU toxicity. FDA-labeled variant.",
        "limitations": [
          "CRITICAL SAFETY - avoid fluoropyrimidines in carriers"
        ]
      },
      "evidence": [
        {
          "pmid": "23988873",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        },
        {
          "pmid": "31994388",
          "study_type": "FDA Label",
          "n": 100000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs56038477",
      "chr": "1",
      "pos": 98348885,
      "ref": "C",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "DPYD",
      "trait": "5-Fluorouracil Toxicity (HapB3)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "HapB3",
        "function": "Decreased",
        "activity_score": 0.5
      },
      "interpretation": {
        "plain_language": "DPYD HapB3 haplotype causes reduced DPD activity. Associated with increased 5-FU toxicity risk. Requires dose reduction.",
        "limitations": [
          "CRITICAL SAFETY - 50% dose reduction recommended"
        ]
      },
      "evidence": [
        {
          "pmid": "23988873",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs6277",
      "chr": "11",
      "pos": 113283688,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "DRD2",
      "star_allele": "C957T",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Dopamine D2 Receptor Function",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "DRD2 C957T affects receptor mRNA stability. May influence antipsychotic response.",
        "clinical_action": "Research marker",
        "limitations": [
          "Not clinically actionable"
        ]
      },
      "evidence": [
        {
          "pmid": "12496935",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs1050828",
      "chr": "X",
      "pos": 154535138,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "G6PD",
      "star_allele": "A-",
      "function": "Decreased",
      "activity_score": 0.1,
      "trait": "G6PD Deficiency",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "drugs_affected": [
        "Primaquine",
        "Chloroquine",
        "Rasburicase",
        "Dapsone",
        "Nitrofurantoin",
        "Sulfamethoxazole"
      ],
      "interpretation": {
        "plain_language": "⛔ CRITICAL: G6PD deficiency causes hemolytic anemia with oxidative stress drugs. X-linked. Males are hemizygous (affected if have variant). Females are carriers/affected if homozygous. Common in Mediterranean, African, Asian populations (antimalarial protection). MANDATORY testing before primaquine.",
        "clinical_action": "⛔ AVOID: Primaquine, rasburicase, dapsone, nitrofurantoin, sulfonamides. Use alternatives. Hemolysis can be SEVERE, potentially fatal. Screen before antimalarial therapy. Avoid fava beans, oxidative stress.",
        "limitations": [
          "X-linked inheritance",
          "Multiple G6PD variants exist",
          "Phenotype testing preferred"
        ]
      },
      "evidence": [
        {
          "pmid": "18596683",
          "study_type": "WHO guidelines",
          "n": 100000,
          "replicated": true
        },
        {
          "pmid": "27281543",
          "study_type": "FDA Label",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true
    },
    {
      "rsid": "rs1050829",
      "chr": "X",
      "pos": 154535272,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "G6PD",
      "star_allele": "A",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "G6PD Deficiency",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "interpretation": {
        "plain_language": "⛔ G6PD deficiency variant. Often occurs with rs1050828 (A- haplotype).",
        "clinical_action": "⛔ Same as rs1050828 - avoid oxidative drugs",
        "limitations": [
          "Part of G6PD haplotype"
        ]
      },
      "evidence": [
        {
          "pmid": "18596683",
          "study_type": "WHO guidelines",
          "n": 100000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true
    },
    {
      "rsid": "rs17868320",
      "chr": "4",
      "pos": 155508513,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "GSTM1",
      "star_allele": "GSTM1 null (proxy)",
      "function": "No function",
      "activity_score": 0,
      "trait": "GST-M1 Deficiency",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "GSTM1 null genotype (~50% of people) lack GST-M1 enzyme. May affect chemotherapy toxicity and carcinogen detoxification.",
        "clinical_action": "Research marker - limited clinical actionability",
        "limitations": [
          "Gene deletion not well-detected on SNP arrays"
        ]
      },
      "evidence": [
        {
          "pmid": "8644707",
          "study_type": "Association study",
          "n": 1000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1695",
      "chr": "11",
      "pos": 67352689,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "GSTP1",
      "star_allele": "I105V",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Glutathione Transferase Activity",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Platinum chemotherapy",
        "Busulfan"
      ],
      "interpretation": {
        "plain_language": "GSTP1 I105V affects glutathione S-transferase Pi, important for chemotherapy detoxification. Val/Val may have altered platinum chemo toxicity/efficacy.",
        "clinical_action": "Research marker for chemotherapy response. Not clinically implemented.",
        "limitations": [
          "Not clinically actionable yet"
        ]
      },
      "evidence": [
        {
          "pmid": "15657417",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs11568820",
      "chr": "6",
      "pos": 18143724,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HIST1H2BJ",
      "star_allele": "Flucloxacillin hepatotoxicity",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Flucloxacillin Hepatotoxicity",
      "clinical_significance": "Risk Factor",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "Near HLA-B*57:01, associated with flucloxacillin hepatotoxicity. Strong GWAS signal.",
        "clinical_action": "Monitor liver function if on flucloxacillin",
        "limitations": [
          "Flucloxacillin not commonly used in US"
        ]
      },
      "evidence": [
        {
          "pmid": "19303062",
          "study_type": "GWAS",
          "n": 800,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1061235",
      "chr": "6",
      "pos": 29911092,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HLA-A",
      "star_allele": "HLA-A*31:01 proxy",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Carbamazepine Hypersensitivity (Europeans)",
      "clinical_significance": "Risk Factor",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Carbamazepine",
        "Phenytoin"
      ],
      "interpretation": {
        "plain_language": "HLA-A*31:01 associated with carbamazepine hypersensitivity in Northern Europeans. Different from HLA-B*15:02 (Asian-specific). May cause DRESS syndrome, SJS/TEN.",
        "clinical_action": "⚠️ European ancestry: Consider alternative anticonvulsant if HLA-A*31:01 positive. FDA awareness statement.",
        "limitations": [
          "European-specific",
          "Lower risk than HLA-B*15:02 in Asians"
        ]
      },
      "evidence": [
        {
          "pmid": "21280076",
          "study_type": "GWAS",
          "n": 1000,
          "replicated": true
        }
      ],
      "confidence": "Moderate",
      "fda_label": true
    },
    {
      "rsid": "rs9934438",
      "chr": "6",
      "pos": 31321611,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HLA-B",
      "star_allele": "HLA-B*13:01 proxy",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Dapsone Hypersensitivity",
      "clinical_significance": "Risk Factor",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "HLA-B*13:01 associated with dapsone hypersensitivity syndrome in Asian populations.",
        "clinical_action": "Monitor closely if on dapsone",
        "limitations": [
          "Asian-specific association"
        ]
      },
      "evidence": [
        {
          "pmid": "23471405",
          "study_type": "GWAS",
          "n": 800,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs2395029",
      "chr": "6",
      "pos": 31324988,
      "ref": "G",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HLA-B",
      "star_allele": "HLA-B*57:01 proxy",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Abacavir Hypersensitivity",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Abacavir"
      ],
      "interpretation": {
        "plain_language": "⛔ CRITICAL: HLA-B*57:01 positive patients have 50-90% risk of severe, potentially FATAL hypersensitivity reaction to abacavir (HIV drug). Symptoms: fever, rash, GI, respiratory distress within 1-6 weeks. Can be fatal if rechallenge. MANDATORY pretreatment testing.",
        "clinical_action": "⛔ CRITICAL: HLA-B*57:01 positive: NEVER prescribe abacavir. Use alternative ARV. FDA BLACK BOX WARNING. MANDATORY testing before abacavir. If positive, document in medical record.",
        "limitations": [
          "rs2395029 is imperfect proxy - direct HLA-B*57:01 typing preferred",
          "FDA MANDATED testing"
        ]
      },
      "evidence": [
        {
          "pmid": "18192896",
          "study_type": "Clinical trial PREDICT-1",
          "n": 1900,
          "replicated": true
        },
        {
          "pmid": "22378157",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "fda_required_testing": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs2276707",
      "chr": "6",
      "pos": 31356399,
      "ref": "C",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HLA-B",
      "star_allele": "HLA-B*58:01 proxy",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Allopurinol Hypersensitivity",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Allopurinol"
      ],
      "interpretation": {
        "plain_language": "⚠️ HLA-B*58:01 strongly predicts severe cutaneous adverse reactions (SCAR) to allopurinol, including SJS/TEN. 100-fold increased risk. VERY COMMON in Han Chinese (~10%), less in Europeans (~1%).",
        "clinical_action": "⚠️ STRONG RECOMMENDATION: Test before allopurinol in Asian patients. If positive, use alternative (febuxostat, pegloticase). CPIC recommends allopurinol-alternative for B*58:01 carriers.",
        "limitations": [
          "rs2276707 is proxy - direct HLA-B*58:01 typing better",
          "Critical for Asian populations"
        ]
      },
      "evidence": [
        {
          "pmid": "18223385",
          "study_type": "GWAS",
          "n": 200,
          "replicated": true
        },
        {
          "pmid": "25801187",
          "study_type": "CPIC Guidelines",
          "n": 10000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "cpic_level": "A"
    },
    {
      "rsid": "rs3909184",
      "chr": "6",
      "pos": 31357456,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HLA-B",
      "star_allele": "HLA-B*15:02 proxy",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Carbamazepine Hypersensitivity (Stevens-Johnson Syndrome)",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Carbamazepine",
        "Oxcarbazepine",
        "Phenytoin"
      ],
      "interpretation": {
        "plain_language": "⛔ CRITICAL: HLA-B*15:02 carriers have dramatically increased risk of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) from carbamazepine. SJS/TEN are life-threatening skin reactions (mortality ~30%). VERY COMMON in East/Southeast Asians (~10%). FDA recommends testing for Asian patients.",
        "clinical_action": "⛔ CRITICAL: HLA-B*15:02 positive: AVOID carbamazepine, oxcarbazepine, phenytoin. Use alternatives (valproate, levetiracetam, lamotrigine). FDA recommendation for Asian ancestry. If SJS/TEN occurs, NEVER rechallenge.",
        "limitations": [
          "rs3909184 is proxy - direct HLA-B*15:02 typing better",
          "FDA recommendation for Asian patients",
          "Critical for Asian populations"
        ]
      },
      "evidence": [
        {
          "pmid": "15057820",
          "study_type": "Association study",
          "n": 200,
          "replicated": true
        },
        {
          "pmid": "26094938",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs2076530",
      "chr": "6",
      "pos": 31434847,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HLA-DQA1",
      "star_allele": "HLA-DQA1*05:01 proxy",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Lapatinib Hepatotoxicity",
      "clinical_significance": "Risk Factor",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Lapatinib"
      ],
      "interpretation": {
        "plain_language": "HLA-DQA1*05:01 associated with increased lapatinib (breast cancer drug) hepatotoxicity.",
        "clinical_action": "Monitor liver function closely if positive",
        "limitations": [
          "Moderate association",
          "Lapatinib not widely used now"
        ]
      },
      "evidence": [
        {
          "pmid": "22327623",
          "study_type": "GWAS",
          "n": 800,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs9462027",
      "chr": "6",
      "pos": 32665748,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HLA-DRB1",
      "star_allele": "HLA-DRB1*07:01 proxy",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Lapatinib Hepatotoxicity",
      "clinical_significance": "Risk Factor",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "HLA-DRB1*07:01 associated with lapatinib hepatotoxicity.",
        "clinical_action": "Monitor liver function",
        "limitations": [
          "Lapatinib use declining"
        ]
      },
      "evidence": [
        {
          "pmid": "22327623",
          "study_type": "GWAS",
          "n": 800,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs6314",
      "chr": "13",
      "pos": 47400026,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HTR2A",
      "star_allele": "His452Tyr",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Serotonin 2A Receptor Function",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "HTR2A His452Tyr affects receptor signaling. May influence clozapine response.",
        "clinical_action": "Research marker",
        "limitations": [
          "Not clinically actionable"
        ]
      },
      "evidence": [
        {
          "pmid": "16249421",
          "study_type": "Meta-analysis",
          "n": 2000,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs6313",
      "chr": "13",
      "pos": 47471478,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "HTR2A",
      "star_allele": "T102C",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Serotonin 2A Receptor & SSRI Response",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "SSRIs",
        "Atypical antipsychotics"
      ],
      "interpretation": {
        "plain_language": "HTR2A T102C may affect SSRI and atypical antipsychotic response. Meta-analyses show modest associations with antidepressant efficacy.",
        "clinical_action": "Research marker - not clinically implemented",
        "limitations": [
          "Inconsistent findings",
          "Small effect sizes"
        ]
      },
      "evidence": [
        {
          "pmid": "16249421",
          "study_type": "Meta-analysis",
          "n": 2000,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs12979860",
      "chr": "19",
      "pos": 39738787,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "IFNL3",
      "star_allele": "IL28B",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Hepatitis C Treatment Response",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "High",
      "drugs_affected": [
        "Peginterferon alfa",
        "Ribavirin"
      ],
      "interpretation": {
        "plain_language": "IFNL3/IL28B variant predicts Hepatitis C treatment response to interferon-based therapy. CC genotype: 2-3x higher sustained virologic response (SVR) vs TT. Less relevant now with DAAs (direct-acting antivirals) which have >95% cure rate regardless of genotype.",
        "clinical_action": "Historical importance: CC favorable for interferon. Modern: DAAs (sofosbuvir, ledipasvir) preferred regardless of genotype. May still influence DAA treatment duration in some cases.",
        "limitations": [
          "Less relevant with modern DAA therapy",
          "Still used for treatment duration decisions"
        ]
      },
      "evidence": [
        {
          "pmid": "19684573",
          "study_type": "GWAS",
          "n": 1600,
          "replicated": true
        },
        {
          "pmid": "20140958",
          "study_type": "Meta-analysis",
          "n": 10000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1801131",
      "chr": "1",
      "pos": 11794419,
      "ref": "A",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics",
        "Nutrigenomics"
      ],
      "gene": "MTHFR",
      "star_allele": "A1298C",
      "function": "Decreased",
      "activity_score": 0.7,
      "trait": "Folate Metabolism",
      "clinical_significance": "Risk Factor",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "MTHFR A1298C has milder effect than C677T. Compound heterozygotes (677T/1298C) have additive reduction in activity.",
        "clinical_action": "Consider in combination with C677T for methotrexate risk assessment",
        "limitations": [
          "Milder effect than C677T alone"
        ]
      },
      "evidence": [
        {
          "pmid": "15060097",
          "study_type": "Meta-analysis",
          "n": 5000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1801133",
      "chr": "1",
      "pos": 11796321,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics",
        "Nutrigenomics"
      ],
      "gene": "MTHFR",
      "star_allele": "C677T",
      "function": "Decreased",
      "activity_score": 0.3,
      "trait": "Folate Metabolism & Methotrexate Response",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Methotrexate",
        "5-Fluorouracil"
      ],
      "interpretation": {
        "plain_language": "MTHFR C677T reduces enzyme activity 30-70%. TT genotype = thermolabile variant. Important for methotrexate (chemotherapy/RA drug) toxicity risk. Also affects folate metabolism and homocysteine levels.",
        "clinical_action": "⚠️ METHOTREXATE: TT genotype may have increased toxicity risk (mucositis, myelosuppression). Ensure adequate folate supplementation. Monitor closely. May need dose reduction.",
        "limitations": [
          "Folate status modifies risk",
          "Clinical significance for MTX debated"
        ]
      },
      "evidence": [
        {
          "pmid": "18779510",
          "study_type": "Meta-analysis",
          "n": 16849,
          "replicated": true
        },
        {
          "pmid": "19776626",
          "study_type": "MTX toxicity meta-analysis",
          "n": 3000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1801394",
      "chr": "5",
      "pos": 7901501,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics",
        "Nutrigenomics"
      ],
      "gene": "MTRR",
      "star_allele": "A66G",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Methotrexate Response & B12 Metabolism",
      "clinical_significance": "Uncertain",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "MTRR A66G affects methionine synthase reductase, involved in B12-dependent homocysteine metabolism. May interact with MTHFR for methotrexate toxicity.",
        "clinical_action": "Consider with MTHFR status for methotrexate risk assessment",
        "limitations": [
          "Interactions complex",
          "Clinical utility debated"
        ]
      },
      "evidence": [
        {
          "pmid": "12023983",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1801280",
      "chr": "8",
      "pos": 18257854,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "NAT2",
      "star_allele": "*5",
      "function": "Decreased",
      "activity_score": 0,
      "trait": "NAT2 Slow Acetylator",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Isoniazid",
        "Hydralazine",
        "Procainamide",
        "Sulfamethoxazole",
        "Sulfasalazine",
        "Dapsone"
      ],
      "interpretation": {
        "plain_language": "NAT2 slow acetylator status affects drug metabolism and toxicity risk. Two slow alleles = slow acetylator (~50% Europeans, ~10% Asians). Slow acetylators have 3-4x increased isoniazid hepatotoxicity risk and higher peripheral neuropathy risk.",
        "clinical_action": "⚠️ ISONIAZID: Slow acetylators: Vitamin B6 supplementation (25-50mg daily) MANDATORY to prevent peripheral neuropathy. Monitor liver function monthly. Consider shorter TB treatment if slow acetylator. Hydralazine/procainamide: Increased lupus-like syndrome risk.",
        "limitations": [
          "Multiple NAT2 variants determine acetylator status",
          "Environmental factors also affect toxicity"
        ]
      },
      "evidence": [
        {
          "pmid": "10912058",
          "study_type": "Association study",
          "n": 1000,
          "replicated": true
        },
        {
          "pmid": "25801187",
          "study_type": "Meta-analysis",
          "n": 20000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "cpic_level": "A"
    },
    {
      "rsid": "rs1801279",
      "chr": "8",
      "pos": 18257906,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "NAT2",
      "star_allele": "*14",
      "function": "Decreased",
      "activity_score": 0,
      "trait": "NAT2 Slow Acetylator",
      "clinical_significance": "Risk Factor",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "NAT2*14 slow acetylator allele.",
        "clinical_action": "Same as other slow acetylator alleles",
        "limitations": [
          "Less common variant"
        ]
      },
      "evidence": [
        {
          "pmid": "10912058",
          "study_type": "Association study",
          "n": 1000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1799930",
      "chr": "8",
      "pos": 18258103,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "NAT2",
      "trait": "Drug Metabolism (NAT2*6A G590A)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*6",
        "function": "Decreased",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "NAT2*6 is a slow acetylator allele. Affects metabolism of isoniazid, sulfonamides, and hydralazine. Slow acetylators have increased isoniazid hepatotoxicity risk.",
        "limitations": [
          "Important for tuberculosis treatment monitoring"
        ]
      },
      "evidence": [
        {
          "pmid": "10912058",
          "study_type": "Association study",
          "n": 1000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1799931",
      "chr": "8",
      "pos": 18258581,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "NAT2",
      "star_allele": "*7",
      "function": "Decreased",
      "activity_score": 0,
      "trait": "NAT2 Slow Acetylator",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "interpretation": {
        "plain_language": "NAT2*7 slow acetylator allele.",
        "clinical_action": "Same as *5/*6",
        "limitations": [
          "Part of NAT2 haplotype"
        ]
      },
      "evidence": [
        {
          "pmid": "10912058",
          "study_type": "Association study",
          "n": 1000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs186364861",
      "chr": "13",
      "pos": 48611668,
      "ref": "C",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "NUDT15",
      "star_allele": "*4",
      "function": "No function",
      "activity_score": 0,
      "trait": "NUDT15 Deficiency",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "⛔ CRITICAL: NUDT15*4 causes enzyme deficiency. Less common than *2/*3.",
        "clinical_action": "⛔ Same as *2/*3",
        "limitations": [
          "Rarer variant"
        ]
      },
      "evidence": [
        {
          "pmid": "27492096",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs147390019",
      "chr": "13",
      "pos": 48611790,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "NUDT15",
      "trait": "Thiopurine Toxicity Risk (NUDT15*3)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*3",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "NUDT15*3 (R139C) is the most common East Asian loss-of-function variant. CRITICAL: Associated with severe thiopurine toxicity. FDA-labeled.",
        "limitations": [
          "CRITICAL SAFETY - most important NUDT15 variant to test"
        ]
      },
      "evidence": [
        {
          "pmid": "27492096",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        },
        {
          "pmid": "28498052",
          "study_type": "FDA Label",
          "n": 10000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs116855232",
      "chr": "13",
      "pos": 48611934,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "NUDT15",
      "trait": "Thiopurine Toxicity Risk (NUDT15*2)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*2",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "NUDT15*2 causes complete loss of enzyme function. CRITICAL: Homozygotes have severe early leukopenia from thiopurines. Common in East Asian populations (10% carrier frequency). FDA-labeled pharmacogenomic marker.",
        "limitations": [
          "CRITICAL SAFETY - avoid thiopurines or use 10% dose in homozygotes"
        ]
      },
      "evidence": [
        {
          "pmid": "27492096",
          "study_type": "CPIC Guidelines",
          "n": 50000,
          "replicated": true
        },
        {
          "pmid": "28498052",
          "study_type": "FDA Label",
          "n": 10000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1799971",
      "chr": "6",
      "pos": 154039662,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "OPRM1",
      "star_allele": "A118G",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Opioid Response (mu-opioid receptor)",
      "clinical_significance": "Uncertain",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "OPRM1 A118G may affect opioid analgesic response and addiction risk. GG genotype may require higher opioid doses for analgesia. Also associated with alcohol dependence risk.",
        "clinical_action": "May consider in pain management - GG patients may need higher doses. Not definitive.",
        "limitations": [
          "Clinical utility debated",
          "Multiple factors affect opioid response"
        ]
      },
      "evidence": [
        {
          "pmid": "15286701",
          "study_type": "Meta-analysis",
          "n": 3000,
          "replicated": true
        },
        {
          "pmid": "16365411",
          "study_type": "Association study",
          "n": 1000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs662",
      "chr": "7",
      "pos": 95308134,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "PON1",
      "star_allele": "Q192R",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Organophosphate Metabolism",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "drugs_affected": [
        "Organophosphate pesticides",
        "Nerve agents"
      ],
      "interpretation": {
        "plain_language": "PON1 Q192R affects paraoxonase 1 enzyme that detoxifies organophosphates. RR genotype has higher activity against certain substrates (paraoxon) but lower against others.",
        "clinical_action": "Relevant for occupational/military exposure to organophosphates. May affect sarin/VX detoxification capacity.",
        "limitations": [
          "Substrate-dependent activity",
          "Not commonly clinically relevant"
        ]
      },
      "evidence": [
        {
          "pmid": "9603939",
          "study_type": "Association study",
          "n": 1500,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs854560",
      "chr": "7",
      "pos": 95308197,
      "ref": "A",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "PON1",
      "star_allele": "L55M",
      "function": "Variable",
      "activity_score": 1,
      "trait": "PON1 Expression",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "PON1 L55M affects enzyme levels. Interacts with Q192R.",
        "clinical_action": "Part of PON1 haplotype assessment",
        "limitations": [
          "Interacts with Q192R variant"
        ]
      },
      "evidence": [
        {
          "pmid": "9603939",
          "study_type": "Association study",
          "n": 1500,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs1051266",
      "chr": "19",
      "pos": 49206674,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "SLC19A1",
      "star_allele": "RFC1 G80A",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Methotrexate Transport",
      "clinical_significance": "Uncertain",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "SLC19A1/RFC1 variant may affect methotrexate transport and toxicity. Clinical significance under investigation.",
        "clinical_action": "Research marker - no clinical recommendations yet",
        "limitations": [
          "Not clinically actionable"
        ]
      },
      "evidence": [
        {
          "pmid": "18202412",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs25531",
      "chr": "17",
      "pos": 28562856,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "SLC6A4",
      "star_allele": "5-HTTLPR STin2",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Serotonin Transporter & SSRI Response",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "SLC6A4 STin2 (with 5-HTTLPR VNTR) affects serotonin transporter expression. May influence SSRI response and adverse effects.",
        "clinical_action": "Research marker - STAR*D trial showed associations but not clinically implemented",
        "limitations": [
          "Needs 5-HTTLPR VNTR which SNP arrays don't detect well"
        ]
      },
      "evidence": [
        {
          "pmid": "17592478",
          "study_type": "STAR*D",
          "n": 2000,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs4149056",
      "chr": "12",
      "pos": 21176804,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "SLCO1B1",
      "star_allele": "*5",
      "function": "Decreased",
      "activity_score": 0.3,
      "trait": "Statin-Induced Myopathy Risk",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Simvastatin",
        "Atorvastatin",
        "Pravastatin",
        "Rosuvastatin",
        "Pitavastatin"
      ],
      "interpretation": {
        "plain_language": "SLCO1B1*5 (V174A) reduces hepatic statin uptake, increasing blood levels and myopathy risk. STRONGEST genetic predictor of statin myopathy. CC genotype: 17-fold increased simvastatin myopathy risk at 80mg dose, 4-fold at 40mg. FDA-labeled.",
        "clinical_action": "⚠️ SIMVASTATIN: CC genotype: AVOID >40mg dose. Use ≤20mg or switch to pravastatin/rosuvastatin. CT: Use ≤40mg. Atorvastatin: Lower doses preferred if CC. Pravastatin/rosuvastatin: Less affected, preferred alternatives.",
        "limitations": [
          "Simvastatin most affected, pravastatin/rosuvastatin least affected"
        ]
      },
      "evidence": [
        {
          "pmid": "18650507",
          "study_type": "GWAS",
          "n": 300000,
          "replicated": true
        },
        {
          "pmid": "24918167",
          "study_type": "Clinical implementation",
          "n": 2000,
          "replicated": true
        },
        {
          "pmid": "21878672",
          "study_type": "Meta-analysis",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs2306283",
      "chr": "12",
      "pos": 21196951,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "SLCO1B1",
      "trait": "Statin Transport (SLCO1B1*1b)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*1b",
        "function": "Normal"
      },
      "interpretation": {
        "plain_language": "SLCO1B1*1b is a common haplotype marker. When combined with rs4149056 (C), defines the *15 and *17 decreased function haplotypes.",
        "limitations": [
          "Used in compound haplotype determination"
        ]
      },
      "evidence": [
        {
          "pmid": "18650507",
          "study_type": "GWAS",
          "n": 300000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs2289669",
      "chr": "12",
      "pos": 21284127,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "SLCO1B3",
      "star_allele": "Intron variant",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Drug Transport",
      "clinical_significance": "Uncertain",
      "evidence_level": "Low",
      "interpretation": {
        "plain_language": "SLCO1B3 variant, clinical significance unclear.",
        "clinical_action": "No clinical recommendations",
        "limitations": [
          "Not clinically actionable"
        ]
      },
      "evidence": [
        {
          "pmid": "16141476",
          "study_type": "Association study",
          "n": 300,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs4148738",
      "chr": "12",
      "pos": 21284481,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "SLCO1B3",
      "star_allele": "Promoter variant",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Drug Transport",
      "clinical_significance": "Uncertain",
      "evidence_level": "Low",
      "interpretation": {
        "plain_language": "SLCO1B3 promoter variant.",
        "clinical_action": "No clinical recommendations",
        "limitations": [
          "Not clinically actionable"
        ]
      },
      "evidence": [
        {
          "pmid": "16141476",
          "study_type": "Association study",
          "n": 300,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs2242480",
      "chr": "12",
      "pos": 21331549,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "SLCO1B3",
      "star_allele": "699G>A",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Drug Transport",
      "clinical_significance": "Uncertain",
      "evidence_level": "Low",
      "interpretation": {
        "plain_language": "SLCO1B3 variant, may affect transport function.",
        "clinical_action": "No clinical recommendations",
        "limitations": [
          "Not clinically actionable"
        ]
      },
      "evidence": [
        {
          "pmid": "16141476",
          "study_type": "Association study",
          "n": 300,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs4149117",
      "chr": "12",
      "pos": 21331650,
      "ref": "T",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "SLCO1B3",
      "star_allele": "334T>G",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Drug Transport",
      "clinical_significance": "Pharmacogenomic",
      "evidence_level": "Low",
      "interpretation": {
        "plain_language": "SLCO1B3 variant may affect drug transport. Less well-studied than SLCO1B1.",
        "clinical_action": "Research marker",
        "limitations": [
          "Clinical significance unclear"
        ]
      },
      "evidence": [
        {
          "pmid": "16141476",
          "study_type": "Association study",
          "n": 300,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs4986790",
      "chr": "9",
      "pos": 117713024,
      "ref": "A",
      "alt": "G",
      "category": [
        "Health",
        "Pharmacogenomics",
        "Immunology"
      ],
      "gene": "TLR4",
      "star_allele": "D299G",
      "function": "Variable",
      "activity_score": 1,
      "trait": "Innate Immunity & Sepsis Risk",
      "clinical_significance": "Risk Factor",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "TLR4 D299G affects Toll-like receptor 4 function, important for bacterial LPS recognition. May affect sepsis risk and response to Gram-negative infections.",
        "clinical_action": "Research marker - no clinical recommendations. May affect vaccine response.",
        "limitations": [
          "Not clinically actionable"
        ]
      },
      "evidence": [
        {
          "pmid": "12023369",
          "study_type": "Discovery",
          "n": 200,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs1142345",
      "chr": "6",
      "pos": 18130687,
      "ref": "A",
      "alt": "C",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "TPMT",
      "star_allele": "*3A (component) / *3C",
      "function": "No function",
      "activity_score": 0,
      "trait": "TPMT Deficiency - Thiopurine Toxicity",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "interpretation": {
        "plain_language": "⛔ CRITICAL: TPMT variant causing enzyme deficiency. Part of *3A (with rs1800460) or *3C alone. Same critical safety implications as rs1800460.",
        "clinical_action": "⛔ CRITICAL: Same as rs1800460 - avoid or drastically reduce thiopurines",
        "limitations": [
          "MANDATORY testing"
        ]
      },
      "evidence": [
        {
          "pmid": "23422873",
          "study_type": "CPIC Guidelines",
          "n": 100000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs1800462",
      "chr": "6",
      "pos": 18130918,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "TPMT",
      "trait": "Thiopurine Toxicity Risk (TPMT*2)",
      "risk_model": {
        "type": "star_allele",
        "star_allele": "*2",
        "function": "No function",
        "activity_score": 0
      },
      "interpretation": {
        "plain_language": "TPMT*2 causes complete loss of enzyme function. CRITICAL: Homozygotes have severe, potentially fatal toxicity risk from thiopurines (azathioprine, 6-MP, thioguanine).",
        "limitations": [
          "MANDATORY testing before thiopurine prescription"
        ]
      },
      "evidence": [
        {
          "pmid": "23422873",
          "study_type": "CPIC Guidelines",
          "n": 100000,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs1800584",
      "chr": "6",
      "pos": 18133838,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "TPMT",
      "star_allele": "*3D",
      "function": "No function",
      "activity_score": 0,
      "trait": "TPMT Deficiency",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "TPMT*3D causes enzyme deficiency. Less common than *3A.",
        "clinical_action": "⛔ Same as other TPMT deficiency alleles - avoid/reduce thiopurines",
        "limitations": [
          "Rarer variant"
        ]
      },
      "evidence": [
        {
          "pmid": "23422873",
          "study_type": "CPIC Guidelines",
          "n": 100000,
          "replicated": true
        }
      ],
      "confidence": "Moderate",
      "cpic_level": "A"
    },
    {
      "rsid": "rs1800460",
      "chr": "6",
      "pos": 18139228,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "TPMT",
      "star_allele": "*3A (component)",
      "function": "No function",
      "activity_score": 0,
      "trait": "TPMT Deficiency - Thiopurine Toxicity",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "drugs_affected": [
        "Azathioprine",
        "6-Mercaptopurine",
        "6-Thioguanine"
      ],
      "interpretation": {
        "plain_language": "⛔ CRITICAL SAFETY FINDING: TPMT deficiency causes SEVERE, POTENTIALLY FATAL bone marrow toxicity from thiopurines (azathioprine, 6-MP, thioguanine). Used for autoimmune diseases, IBD, ALL. Deficiency frequency: ~0.3% homozygous, ~10% heterozygous. This is MANDATORY pretreatment testing.",
        "clinical_action": "⛔ CRITICAL: Homozygous deficient (e.g. *3A/*3A): AVOID thiopurines or reduce to 10% dose with intensive monitoring. Heterozygous: 30-80% dose reduction, weekly CBC × 4 weeks. LIFE-THREATENING myelosuppression risk.",
        "limitations": [
          "MANDATORY testing before thiopurine prescription",
          "rs1800460 + rs1142345 together define *3A"
        ]
      },
      "evidence": [
        {
          "pmid": "23422873",
          "study_type": "CPIC Guidelines",
          "n": 100000,
          "replicated": true
        },
        {
          "pmid": "21270794",
          "study_type": "Systematic review",
          "n": 50000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs7294",
      "chr": "19",
      "pos": 15990431,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "TYMS",
      "star_allele": "TYMS variant",
      "function": "Variable",
      "activity_score": 1,
      "trait": "5-FU Response (thymidylate synthase)",
      "clinical_significance": "Uncertain",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "TYMS variants may affect 5-fluorouracil efficacy (cancer treatment). Higher TYMS expression associated with 5-FU resistance.",
        "clinical_action": "Research marker - not clinically implemented",
        "limitations": [
          "Not clinically actionable yet"
        ]
      },
      "evidence": [
        {
          "pmid": "11896112",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs17244841",
      "chr": "19",
      "pos": 15990431,
      "ref": "A",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "TYMS",
      "star_allele": "5'UTR VNTR",
      "function": "Variable",
      "activity_score": 1,
      "trait": "5-FU Efficacy",
      "clinical_significance": "Uncertain",
      "evidence_level": "Low",
      "interpretation": {
        "plain_language": "TYMS 5'UTR VNTR affects thymidylate synthase expression and 5-FU efficacy.",
        "clinical_action": "Research marker - not clinically implemented",
        "limitations": [
          "Not clinically actionable"
        ]
      },
      "evidence": [
        {
          "pmid": "11896112",
          "study_type": "Association study",
          "n": 500,
          "replicated": true
        }
      ],
      "confidence": "Low"
    },
    {
      "rsid": "rs8175347",
      "chr": "2",
      "pos": 234668879,
      "ref": "TA(6)",
      "alt": "TA(7)",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "UGT1A1",
      "star_allele": "*28",
      "function": "Decreased",
      "activity_score": 0.3,
      "trait": "UGT1A1 Gilbert Syndrome & Irinotecan Toxicity",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Irinotecan",
        "Nilotinib",
        "Belinostat"
      ],
      "interpretation": {
        "plain_language": "UGT1A1*28 (7 TA repeats vs normal 6) causes reduced enzyme expression (~30% activity). Homozygotes have Gilbert syndrome (mild unconjugated hyperbilirubinemia). CRITICAL for irinotecan chemotherapy - significantly increased severe diarrhea and neutropenia risk. ~10% Europeans homozygous.",
        "clinical_action": "⚠️ IRINOTECAN: *28/*28 homozygous: Reduce starting dose by 30%. Monitor closely for severe diarrhea/neutropenia. FDA-labeled. Heterozygous: Standard dose but monitor closely. Gilbert syndrome: Benign, no treatment needed, avoid fasting.",
        "limitations": [
          "TA repeat may not be well-detected on SNP arrays",
          "FDA-labeled"
        ]
      },
      "evidence": [
        {
          "pmid": "15883587",
          "study_type": "Clinical trial",
          "n": 250,
          "replicated": true
        },
        {
          "pmid": "16116063",
          "study_type": "Meta-analysis",
          "n": 10000,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    },
    {
      "rsid": "rs4148323",
      "chr": "2",
      "pos": 234676872,
      "ref": "G",
      "alt": "A",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "UGT1A1",
      "star_allele": "*6",
      "function": "Decreased",
      "activity_score": 0.3,
      "trait": "UGT1A1 Deficiency",
      "clinical_significance": "Pathogenic",
      "evidence_level": "High",
      "interpretation": {
        "plain_language": "UGT1A1*6 common in East Asian populations (~20%). Causes Gilbert-like syndrome and increased irinotecan toxicity.",
        "clinical_action": "⚠️ Irinotecan: Reduce dose by 30% if homozygous",
        "limitations": [
          "East Asian specific"
        ]
      },
      "evidence": [
        {
          "pmid": "15883587",
          "study_type": "Clinical trial",
          "n": 250,
          "replicated": true
        }
      ],
      "confidence": "High"
    },
    {
      "rsid": "rs887829",
      "chr": "2",
      "pos": 234676872,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "UGT1A1",
      "star_allele": "*27",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "UGT1A1 Intermediate",
      "clinical_significance": "Pathogenic",
      "evidence_level": "Moderate",
      "interpretation": {
        "plain_language": "UGT1A1*27 reduces enzyme activity. African-specific variant.",
        "clinical_action": "Monitor irinotecan toxicity",
        "limitations": [
          "African ancestry"
        ]
      },
      "evidence": [
        {
          "pmid": "15883587",
          "study_type": "Clinical trial",
          "n": 250,
          "replicated": true
        }
      ],
      "confidence": "Moderate"
    },
    {
      "rsid": "rs9923231",
      "chr": "16",
      "pos": 31096368,
      "ref": "C",
      "alt": "T",
      "category": [
        "Health",
        "Pharmacogenomics"
      ],
      "gene": "VKORC1",
      "star_allele": "-1639G>A",
      "function": "Decreased",
      "activity_score": 0.5,
      "trait": "Warfarin Sensitivity",
      "clinical_significance": "Risk Factor",
      "evidence_level": "High",
      "drugs_affected": [
        "Warfarin",
        "Acenocoumarol",
        "Phenprocoumon"
      ],
      "interpretation": {
        "plain_language": "VKORC1 -1639G>A is THE most important warfarin sensitivity variant. T allele (low-dose haplotype) causes significantly increased warfarin sensitivity. TT genotype needs ~30-50% lower warfarin dose. FDA-labeled. Explains ~25% of warfarin dose variance (CYP2C9 + VKORC1 together explain ~40%).",
        "clinical_action": "⚠️ WARFARIN: TT genotype: Start 0.5-2mg, target 2-3mg maintenance. CT: Start 3-4mg, target 3-5mg. CC: Standard 5-7mg dosing. Monitor INR 2-3x weekly initially. Use warfarin dosing algorithms (IWPC, Gage) incorporating both VKORC1 and CYP2C9.",
        "limitations": [
          "Must be used WITH CYP2C9 status",
          "Other factors affect dosing (age, weight, interacting meds)"
        ]
      },
      "evidence": [
        {
          "pmid": "15930419",
          "study_type": "IWPC warfarin algorithm",
          "n": 2500,
          "replicated": true
        },
        {
          "pmid": "19228618",
          "study_type": "Clinical trial",
          "n": 1015,
          "replicated": true
        }
      ],
      "confidence": "High",
      "fda_label": true,
      "cpic_level": "A"
    }
  ]
}